Updates from the 2018 British Society for Rheumatology conference focus on RA treatment targets and resistance to biologics.
References1. Nikiphorou E, Norton S, Adam Young A, et al. Treating rheumatoid arthritis to target: is low disease activity good enough? Presented at: British Society for Rheumatology Annual Conference; May 1-3, 2018; Liverpool, UK.2. Kearsley-Fleet L, Watson K, Buch MH, et al. Refractory disease in rheumatoid arthritis: results from the British Society of Rheumatology Biologics Register for rheumatoid arthritis. Presented at: British Society for Rheumatology Annual Conference; May 1-3, 2018; Liverpool, UK.
Two studies recently presented at the British Society for Rheumatology Annual Conference in Liverpool, UK, address the following questions1,2:
1. Is low disease activity an acceptable treatment target in RA?
2. What percentage of patients with RA are refractory to biologics?
Scroll through the slides for the answers and the take-home points for clinicians.
CI, confidence interval; DAS28, Disease Activity Score of 28 joints; HAQ, Health Assessment Questionnaire; OR, odds ratio; TNF, tumor necrosis factor.
Disease activity was higher among patients with refractory disease (DAS28, 5.0 vs 3.7; HAQ, 2.0 vs 1.6). In multivariable analysis, older patients (> 50 years; OR, 0.5 [95% CI, 0.4, 0.7]) and those with longer disease duration (> 10 years; OR, 0.7 [95% CI, 0.6, 0.95]) had reduced odds of refractory disease. In addition, patients with greater baseline HAQ (OR, 1.8 [95% CI, 1.4, 2.4]) and patient global assessment (OR, 1.1 [95% CI, 1.0, 1.2]) scores had increased odds of refractory disease.